Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability
- PMID: 22753064
- PMCID: PMC3415522
- DOI: 10.1128/JB.00566-12
Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability
Abstract
Diverse microbial communities chronically colonize the lungs of cystic fibrosis patients. Pyrosequencing of amplicons for hypervariable regions in the 16S rRNA gene generated taxonomic profiles of bacterial communities for sputum genomic DNA samples from 22 patients during a state of clinical stability (outpatients) and 13 patients during acute exacerbation (inpatients). We employed quantitative PCR (qPCR) to confirm the detection of Pseudomonas aeruginosa and Streptococcus by the pyrosequencing data and human oral microbe identification microarray (HOMIM) analysis to determine the species of the streptococci identified by pyrosequencing. We show that outpatient sputum samples have significantly higher bacterial diversity than inpatients, but maintenance treatment with tobramycin did not impact overall diversity. Contrary to the current dogma in the field that Pseudomonas aeruginosa is the dominant organism in the majority of cystic fibrosis patients, Pseudomonas constituted the predominant genera in only half the patient samples analyzed and reported here. The increased fractional representation of Streptococcus in the outpatient cohort relative to the inpatient cohort was the strongest predictor of clinically stable lung disease. The most prevalent streptococci included species typically associated with the oral cavity (Streptococcus salivarius and Streptococcus parasanguis) and the Streptococcus milleri group species. These species of Streptococcus may play an important role in increasing the diversity of the cystic fibrosis lung environment and promoting patient stability.
Figures
References
-
- Ahn J, et al. 2011. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS One 6:e22788 doi:10.1371/journal.pone.0022788 - DOI - PMC - PubMed
-
- Bittar F, Rolain JM. 2010. Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin. Microbiol. Infect. 16:809–820 - PubMed
-
- Cox MJ, et al. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5:e11044 doi:10.1371/journal.pone.0011044 - DOI - PMC - PubMed
-
- Dodge JA, Lewis PA, Stanton M, Wilsher J. 2007. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29:522–526 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 GM106394/GM/NIGMS NIH HHS/United States
- R01-HL074175-09/HL/NHLBI NIH HHS/United States
- UH3 DK083993/DK/NIDDK NIH HHS/United States
- 8 P20 GM103413/GM/NIGMS NIH HHS/United States
- P20 GM103413/GM/NIGMS NIH HHS/United States
- T32GM008704/GM/NIGMS NIH HHS/United States
- R01 AI091702/AI/NIAID NIH HHS/United States
- DE11443/DE/NIDCR NIH HHS/United States
- 5P20RR018787/RR/NCRR NIH HHS/United States
- R01 DE011443/DE/NIDCR NIH HHS/United States
- P20 RR018787/RR/NCRR NIH HHS/United States
- R01 HL074175/HL/NHLBI NIH HHS/United States
- T32 GM008704/GM/NIGMS NIH HHS/United States
- 4UH3DK083993-02/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
